Trillium Therapeutics Inc.
TRIL
TRIL was delisted on the 16th of November, 2021.
24 hedge funds and large institutions have $4.62M invested in Trillium Therapeutics Inc. in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
4% more funds holding
Funds holding: 23 → 24 (+1)
53% less capital invested
Capital invested by funds: $9.91M → $4.62M (-$5.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$1.04M |
| 2 |
Morgan Stanley
New York
|
+$302K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$135K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$121K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$44.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$298K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$40K |
| 3 |
VF
Virtu Financial
New York
|
-$19K |
| 4 |
Jane Street
New York
|
-$2.65K |
| 5 |
Wells Fargo
San Francisco,
California
|
-$733 |
TRIL Hedge Fund Activity: Q1 2019 in Review
24 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Trillium Therapeutics Inc. (TRIL) for Q1 2019, worth a combined $4.62M — down 53% from $9.91M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new TRIL positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 3 trimmed.
The largest buyer was NEA Management Company, adding an estimated $1.04M. The largest seller was Anson Funds Management, exiting entirely with an estimated $298K sold.
- 24 institutional investors held Trillium Therapeutics Inc. (TRIL) as of Q1 2019, up from 23 in Q4 2018.
- Funds reported $4.62M of Trillium Therapeutics Inc. stock for Q1 2019, down 53% quarter-over-quarter.
- 5 funds opened new Trillium Therapeutics Inc. positions in Q1 2019 and 4 closed out, a net change of +1 holder.
- The largest Trillium Therapeutics Inc. buyer in Q1 2019 was NEA Management Company, an estimated $1.04M added.
- The largest Trillium Therapeutics Inc. seller in Q1 2019 was Anson Funds Management, an estimated $298K sold.
Based on aggregated 13F filings for Q1 2019.